{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:02:12Z","timestamp":1780635732414,"version":"3.54.1"},"reference-count":94,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Understanding germline genetic variation is essential for improving human cancer care. Cancer predisposition genetic testing has become a part of the landscape of healthcare. Clinical guidelines have been established to identify individuals with monogenic risk, support variant classification, and guide enhanced cancer surveillance and prevention strategies. However, genetic mechanisms, cancer syndromes, genetic testing, patient education, and high-risk cancer management are often addressed in separate professional domains leading to limited cross-disciplinary understanding and confusion. A review tailored to a broad spectrum of clinicians is necessary to synthesize information, connect key concepts, and clearly define the principles and reasoning underlying recommended practice. Advanced genetic technology identified numerous genes and countless pathogenic variants contributing to a wide range of cancer predispositions. Rapid and accurate next-generation sequencing has enabled the routine use of multi-gene panel testing to stratify cancer risk. In precision cancer therapies, tumor genomic profiling frequently uncovers not only somatic alterations but also germline mutations, revealing additional cancer risk for the patients and their biological relatives. Beyond monogenic risks, the cumulative effect of numerous common polygenic factors can also significantly influence cancer susceptibility. Despite major advances in integrating germline genetic information into cancer care, substantial challenges remain in variant interpretation, precise risk stratification, and implementing personalized screening and prevention strategies. Using several cancer predisposition syndromes as examples, such as breast and ovarian cancer syndrome, Lynch syndrome, and Li-Fraumeni syndrome, the review provides a high-level overview of key concepts, the evolution of knowledge and technology, and the rationale underlying the current clinical management strategies.<\/jats:p>","DOI":"10.3390\/genes17060648","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:58:38Z","timestamp":1780473518000},"page":"648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer Genetic Predisposition and Clinical Applications\u2014A Narrative Review on Germline Genetic Testing, High-Risk Cancer Surveillance and Management"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-5229","authenticated-orcid":false,"given":"Xia","family":"Wang","sequence":"first","affiliation":[{"name":"College of Medicine, Central Michigan University, Mt. Pleasant, MI 48601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic Germline Variants in 10,389 Adult Cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"ref_2","unstructured":"(2026, April 25). NCCN: National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jamaoncol.2025.3875","article-title":"Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women","volume":"11","author":"Keil","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"ref_5","first-page":"539","article-title":"Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer","volume":"1","author":"Merajver","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ng0197-103","article-title":"Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene","volume":"15","author":"Gayther","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1998.16.5.1969","article-title":"BRCA1 and BRCA2: From molecular genetics to clinical medicine","volume":"16","author":"Blackwood","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/301996","article-title":"Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls","volume":"63","author":"Farrington","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101909","DOI":"10.1016\/j.eclinm.2023.101909","article-title":"Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: A report from the prospective Lynch syndrome database","volume":"58","author":"Haupt","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.20106","article-title":"The TP53 tumor suppressor gene: From molecular biology to clinical investigations","volume":"298","author":"Baliakas","year":"2025","journal-title":"J. Intern. Med."},{"key":"ref_15","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (2026, April 23). GeneReviews\u00ae [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1116\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101818","DOI":"10.1016\/j.eclinm.2022.101818","article-title":"ERN GENTURIS tumor surveillance guidelines for individuals with neurofibromatosis type 1","volume":"56","author":"Carton","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e20190660","DOI":"10.1542\/peds.2019-0660","article-title":"Health Supervision for Children with Neurofibromatosis Type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of adults with neurofibromatosis type 1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast Cancer Risk Genes\u2014Association Analysis in More than 113,000 Women","volume":"384","author":"Dorling","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","first-page":"50","article-title":"A blueprint for cancer screening and early detection: Advancing screening\u2019s contribution to cancer control","volume":"69","author":"Wender","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/gutjnl-2015-309675","article-title":"Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: First report from the prospective Lynch syndrome database","volume":"66","author":"Bernstein","year":"2017","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer Risks for PMS2-Associated Lynch Syndrome","volume":"36","author":"Tops","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.27556","article-title":"Clinical significance of large rearrangements in BRCA1 and BRCA2","volume":"118","author":"Judkins","year":"2012","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ejhg.2014.16","article-title":"Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes","volume":"22","author":"Krieger","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jamaoncol.2023.5586","article-title":"Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing","volume":"10","author":"Horton","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2024.10852","article-title":"Germline CDH1 Variants and Lifetime Cancer Risk","volume":"332","author":"Ryan","year":"2024","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/ajmg.a.35560","article-title":"Breast cancer and other neoplasms in women with neurofibromatosis type 1: A retrospective review of cases in the Detroit metropolitan area","volume":"158A","author":"Wang","year":"2012","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","article-title":"Frequency and spectrum of cancers in the Peutz-Jeghers syndrome","volume":"12","author":"Hearle","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ajhg.2025.02.013","article-title":"The contribution of coding variants to the heritability of multiple cancer types using UK Biobank whole-exome sequencing data","volume":"112","author":"Wilcox","year":"2025","journal-title":"Am. J. Hum. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.gim.2021.08.016","article-title":"Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants","volume":"24","author":"Li","year":"2022","journal-title":"Genet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: Insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/jmedgenet-2019-106281","article-title":"Impact of DNA source on genetic variant detection from human whole-genome sequencing data","volume":"56","author":"Trost","year":"2019","journal-title":"J. Med. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.24374","article-title":"Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders","volume":"43","author":"DeRoin","year":"2022","journal-title":"Hum. Mutat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1158\/1055-9965.EPI-06-0859","article-title":"Successful genome-wide scan in paired blood and buccal samples","volume":"16","author":"Feigelson","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Committee on Gynecologic Practice (2018). ACOG Committee Opinion No. 727: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer. Obstet. Gynecol., 131, e31\u2013e34.","DOI":"10.1097\/AOG.0000000000002457"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-016-3891-z","article-title":"Evaluation of an amplicon-based next-generation sequencing panel for detection of BRCA1 and BRCA2 genetic variants","volume":"158","author":"Shin","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/humu.22975","article-title":"What\u2019s in a Name? A Coordinated Approach toward the Correct Use of a Uniform Nomenclature to Improve Patient Reports and Databases","volume":"37","author":"Tack","year":"2016","journal-title":"Hum. Mutat."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Laros, J.F., Blavier, A., den Dunnen, J.T., and Taschner, P.E. (2011). A formalized description of the standard human variant nomenclature in Extended Backus-Naur Form. BMC Bioinform., 12.","DOI":"10.1186\/1471-2105-12-S4-S5"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1002\/cphg.93","article-title":"Overview of Specifications to the ACMG\/AMP Variant Interpretation Guidelines","volume":"103","author":"Harrison","year":"2019","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","volume":"39","author":"Rebbeck","year":"2018","journal-title":"Hum. Mutat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/humu.24291","article-title":"Utilizing ClinGen gene-disease validity and dosage sensitivity curations to inform variant classification","volume":"43","author":"Thaxton","year":"2022","journal-title":"Hum. Mutat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/humu.23645","article-title":"ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG\/AMP guidelines for sequence variant interpretation","volume":"39","author":"Milko","year":"2018","journal-title":"Hum. Mutat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ajhg.2017.04.015","article-title":"Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource","volume":"100","author":"Strande","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa031759","article-title":"Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition","volume":"351","author":"Kriege","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1470-2045(19)30275-X","article-title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): A multicentre, randomised, controlled trial","volume":"20","author":"Saadatmand","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1148\/radiol.2017170458","article-title":"Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk","volume":"286","author":"Vreemann","year":"2018","journal-title":"Radiology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1148\/radiol.2016161106","article-title":"MR imaging for diagnosis of malignancy in mammographic microcalcifications: A systematic review and meta-analysis","volume":"283","author":"Baltzer","year":"2017","journal-title":"Radiology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2500264","DOI":"10.1200\/PO-25-00264","article-title":"Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni Syndrome","volume":"9","author":"Maoz","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"105541","DOI":"10.1016\/j.esmoop.2025.105541","article-title":"Li Fraumeni syndrome in the UK: Clinical characteristics and outcomes of TP53 carriers","volume":"10","author":"Finn","year":"2025","journal-title":"ESMO Open"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/jmg-2025-110704","article-title":"Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome","volume":"62","author":"Sodde","year":"2025","journal-title":"J. Med. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2400642","DOI":"10.1200\/PO-24-00642","article-title":"Utility of Whole-Body Magnetic Resonance Imaging Surveillance in Children and Adults With Cancer Predisposition Syndromes: A Retrospective Study","volume":"9","author":"Que","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008). Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 371, 303\u2013314.","DOI":"10.1016\/S0140-6736(08)60167-1"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2021.01.014","article-title":"Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: An international cohort study","volume":"225","author":"Schrijver","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","article-title":"Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma","volume":"8","author":"Ducie","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cge.14759","article-title":"Deep Phenotyping of Pathology-Confirmed Benign Lesions in PTEN Hamartoma Tumor Syndrome Patients","volume":"108","author":"Mensenkamp","year":"2025","journal-title":"Clin. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S1470-2045(24)00026-3","article-title":"Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: An International Replication Repair Deficiency Consortium cohort study","volume":"25","author":"Ercan","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jmedgenet-2017-104560","article-title":"The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: Breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium","volume":"55","author":"Moghadasi","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S1470-2045(21)00189-3","article-title":"Variation in the risk of colorectal cancer in families with Lynch syndrome: A retrospective cohort study","volume":"22","author":"Consortium","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.tig.2014.02.006","article-title":"Laying a solid foundation for Manhattan\u2014\u2018Setting the functional basis for the post-GWAS era\u2019","volume":"30","author":"Zhang","year":"2014","journal-title":"Trends Genet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra0905980","article-title":"Genomewide association studies and assessment of the risk of disease","volume":"363","author":"Manolio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"djv036","DOI":"10.1093\/jnci\/djv036","article-title":"Prediction of breast cancer risk based on profiling with common genetic variants","volume":"107","author":"Mavaddat","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41568-023-00599-x","article-title":"Polygenic scores in cancer","volume":"23","author":"Yang","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1055-9965.EPI-24-0594","article-title":"Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk","volume":"33","author":"Kalia","year":"2024","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e2323336","DOI":"10.1001\/jamanetworkopen.2023.23336","article-title":"First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities","volume":"6","author":"Matsubara","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2022.01.006","article-title":"Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing","volume":"33","author":"Terraf","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_76","first-page":"525","article-title":"Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors","volume":"7","author":"Cobain","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1093\/jnci\/djaf057","article-title":"Radiotherapy results in decreased time to second cancer in children with Li Fraumeni syndrome","volume":"117","author":"Woodward","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1002\/cam4.3427","article-title":"Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study","volume":"9","author":"Hendrickson","year":"2020","journal-title":"Cancer Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-020-05612-7","article-title":"Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome","volume":"181","author":"Le","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gim.2021.11.002","article-title":"Points to consider to avoid unfair discrimination and the misuse of genetic information: A statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"24","author":"Seaver","year":"2022","journal-title":"Genet. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","article-title":"Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing","volume":"320","author":"Mersch","year":"2018","journal-title":"JAMA"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Chrysafi, P., Jani, C.T., Lotz, M., Al Omari, O., Singh, H., Stafford, K., Agarwal, L., Rupal, A., Dar, A.Q., and Dangelo, A. (2023). Prevalence of Variants of Uncertain Significance in Patients Undergoing Genetic Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome. Cancers, 15.","DOI":"10.3390\/cancers15245762"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10689-019-00144-6","article-title":"Inequities in multi-gene hereditary cancer testing: Lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European","volume":"18","author":"Issaka","year":"2019","journal-title":"Fam. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cam4.5202","article-title":"A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes","volume":"12","author":"Makhnoon","year":"2023","journal-title":"Cancer Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e2444526","DOI":"10.1001\/jamanetworkopen.2024.44526","article-title":"Clinical Variant Reclassification in Hereditary Disease Genetic Testing","volume":"7","author":"Kobayashi","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1158\/1078-0432.CCR-22-0203","article-title":"Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG\/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay","volume":"28","author":"Hu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41436-018-0372-2","article-title":"A functional assay-based procedure to classify mismatch repair gene variants in Lynch syndrome","volume":"21","author":"Drost","year":"2019","journal-title":"Genet. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/humu.23640","article-title":"Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes","volume":"39","author":"Walsh","year":"2018","journal-title":"Hum. Mutat."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am. J. Hum. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41467-020-20496-3","article-title":"A case-only study to identify genetic modifiers of breast cancer risk for BRCA1\/BRCA2 mutation carriers","volume":"12","author":"Coignard","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41436-020-0862-x","article-title":"Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants","volume":"22","author":"Barnes","year":"2020","journal-title":"Genet. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/2159-8290.CD-23-0456","article-title":"Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA","volume":"14","author":"Wong","year":"2024","journal-title":"Cancer Discov."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/6\/648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:32:54Z","timestamp":1780633974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/6\/648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":94,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["genes17060648"],"URL":"https:\/\/doi.org\/10.3390\/genes17060648","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}